Whitehawk Therapeutics (WHWK) Share-based Compensation (2015 - 2026)

Whitehawk Therapeutics (WHWK) has reported Share-based Compensation for 11 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 30.54% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $9.3 million (up 4.68% YoY), while the FY2025 annual figure was $9.9 million, down 8.91% from the prior year.
• Share-based Compensation declined to $2.2 million in Q1 2026 per WHWK's latest filing, from $2.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $7.9 million in Q3 2025 and bottomed at -$5.5 million in Q4 2022.
• Historically, Share-based Compensation has averaged $2.4 million across 5 years, with a median of $2.7 million in 2023.
• On a YoY basis, Share-based Compensation climbed as much as 5630.77% in 2022 and fell as far as 469.79% in 2022.
• Whitehawk Therapeutics' Share-based Compensation stood at -$5.5 million in 2022, then surged by 156.24% to $3.1 million in 2023, then tumbled by 40.41% to $1.9 million in 2024, then increased by 28.8% to $2.4 million in 2025, then slipped by 8.17% to $2.2 million in 2026.
• Business Quant data shows WHWK's Share-based Compensation at $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $7.9 million in Q3 2025.